Core Viewpoint - Hongyuan Pharmaceutical expects a significant increase in net profit for the fiscal year 2025, driven by the growth in demand for lithium hexafluorophosphate in the electric vehicle and energy storage markets [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 113 million to 137 million yuan, representing a year-on-year growth of 119.57% to 166.20% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 82 million and 106 million yuan, showing a substantial increase of 782.01% to 1040.17% compared to the previous year [1] - The estimated impact of non-recurring gains and losses on net profit is approximately 31 million yuan [1] Business Impact - The performance fluctuation is primarily influenced by the lithium hexafluorophosphate business, which has seen a marked improvement in profitability due to the sustained growth in the new energy vehicle and energy storage markets [1]
宏源药业：预计2025年净利润为1.13亿元至1.37亿元，同比增119.57%至166.20%